Updates In Esophageal & Gastric Cancers: When Dose Of Xeloda & Oxaliplatin Is Reduced In Frail Patients They Did Very Well & Had Less Toxicity
Nicholas Rohs MD @NickRohsMD Of Mount Sinai Discusses Updates In Esophageal & Gastric Cancers: When Dose Of Xeloda & Oxaliplatin Is Reduced In Frail Patients They Did Very Well & Had Less Toxicity.
Author: Annual-Meeting
Added: 06/04/2019 (Source: Oncology Tube)
Source: Oncology Tube - June 4, 2019 Category: Cancer & Oncology Source Type: podcasts
Lower Doses Of Xeloda & Oxaliplatin: Physicians Would Be Happy To Give A Lower Dose If Data Supports
Nicholas Rohs MD @NickRohsMD Of Mount Sinai Discusses Lower Doses Of Xeloda & Oxaliplatin: Physicians Would Be Happy To Give A Lower Dose If Data Supports.
Author: Annual-Meeting
Added: 06/04/2019 (Source: Oncology Tube)
Source: Oncology Tube - June 4, 2019 Category: Cancer & Oncology Source Type: podcasts
Pembrolizumab, Trastuzumab, Capecitabine & Oxaliplatin In HER2+ mEGA
David Ilson, MD, PhD Attending Physician, Memorial Sloan Kettering Cancer Center, Professor of Medicine, Weill Cornell Medical College, Discusses Pembrolizumab, Trastuzumab, Capecitabine & Oxaliplatin...
Author: obr
Added: 02/06/2019 (Source: Oncology Tube)
Source: Oncology Tube - February 6, 2019 Category: Cancer & Oncology Source Type: podcasts
Adjuvant Chemotherapy for Rectal Cancer | Possibly Use Single-Agent Capecitabine
Fa-Chyi Lee, MD, UC Irvine Health, talks about Adjuvant Chemotherapy for Rectal Cancer | Possibly Use Single-Agent Capecitabine at MOASC 2018<br />
Author: moasc
Added: 08/23/2018 (Source: Oncology Tube)
Source: Oncology Tube - August 23, 2018 Category: Cancer & Oncology Source Type: podcasts
Debate: Optimal adjuvant chemotherapy for resected pancreatic cancer - Gemcitabine/capecitabine
In this presentation from the 2017 Great Debates & Updates in GI Malignancies, Dr. Tanios S. Bekaii-Saab argues that gemcitabine/capecitabine is the optimal adjuvant chemotherapy regimen for resected ...
Author: imedex
Added: 08/23/2017 (Source: Oncology Tube)
Source: Oncology Tube - August 23, 2017 Category: Cancer & Oncology Source Type: podcasts
Neratinib and Capecitabine for Patients with HER2+ Breast Cancer Brain Metastases (BCBM)
Daniela Bota, MD of UC Irvine Health discusses the use of neratinib and capecitabine in patients with breast cancer brain metastases at the 2017 MOASC Spotlight on Clinical Oncology in Huntington Beac...
Author: moasc
Added: 08/03/2017 (Source: Oncology Tube)
Source: Oncology Tube - August 3, 2017 Category: Cancer & Oncology Source Type: podcasts
Use of capecitabine in biliary cancers
Philip Philip, MD of Karmanos Cancer Institute gives his take on the use of capecitabine in biliary cancers at the 2017 ASCO Annual Meeting in Chicago, IL.
Author: obr
Added: 06/22/2017 (Source: Oncology Tube)
Source: Oncology Tube - June 22, 2017 Category: Cancer & Oncology Source Type: podcasts
ONT-380 for HER2+ metastatic breast cancer: promising results for patients with brain metastases
Erika Hamilton of Sarah Cannon Research Institute, Nashville, TN talks about a Phase I trial of ONT-380 in combination with capecitabine and T-DM1 (trastuzumab emtansine), in patients with HER2+ metas...
Author: VJOncology
Added: 08/18/2016 (Source: Oncology Tube)
Source: Oncology Tube - August 18, 2016 Category: Cancer & Oncology Source Type: podcasts
JAMA Surgery : Preoperative Chemotherapy and Radiation for Borderline Resectable Pancreatic Cancer
Interview with Matthew H. G. Katz, MD, author of Preoperative Modified FOLFIRINOX Treatment Followed by Capecitabine-Based Chemoradiation for Borderline Resectable Pancreatic Cancer: Alliance for Clinical Trials in Oncology Trial A021101 (Source: JAMA Specialty Journals Author Interviews)
Source: JAMA Specialty Journals Author Interviews - June 8, 2016 Category: Journals (General) Authors: The JAMA Network Source Type: podcasts
Preoperative Chemotherapy and Radiation for Borderline Resectable Pancreatic Cancer (JAMA Surgery)
Interview with Matthew H. G. Katz, MD, author of Preoperative Modified FOLFIRINOX Treatment Followed by Capecitabine-Based Chemoradiation for Borderline Resectable Pancreatic Cancer: Alliance for Clinical Trials in Oncology Trial A021101 (Source: JAMA Specialty Journals Author Interviews)
Source: JAMA Specialty Journals Author Interviews - June 8, 2016 Category: Journals (General) Authors: The JAMA Network Source Type: podcasts
FOLFOX + ziv-aflibercept v. AVAGAST trial of capecitabine-cisplatin with or without bevacizumab in gastric carcinomas at ASCO GI 2016
Daniel Catenacci, MD of The University of Chicago Medicine discusses FOLFOX + ziv-aflibercept v. AVAGAST trial of capecitabine-cisplatin with or without bevacizumab in gastric carcinomas at ASCO GI 20...
Author: ASCOGI2016
Added: 01/26/2016 (Source: Oncology Tube)
Source: Oncology Tube - January 27, 2016 Category: Cancer & Oncology Source Type: podcasts
ASCO GI 2016: FOLFOX + ziv-aflibercept placebo versus AVAGAST trial of capecitabine-cisplatin with or without bevacizumab
Joel Randolph Hecht, MD of UCLA Health discusses FOLFOX + ziv-aflibercept placebo versus AVAGAST trial of capecitabine-cisplatin with or without bevacizumab at ASCO GI 2016
Author: ASCOGI2016
Added: 01/22/2016 (Source: Oncology Tube)
Source: Oncology Tube - January 23, 2016 Category: Cancer & Oncology Source Type: podcasts
Is Capecitabine New Standard in Pre-op Rectal Cancer?
Dr David Kerr reports on a study in which oral capecitabine beat continuous-infusion 5-FU 'fairly and squarely' in tumor control of early rectal cancer, which may prove a new standard of practice. (Source: Medscape Oncology)
Source: Medscape Oncology - January 15, 2016 Category: Cancer & Oncology Authors: Medscape Source Type: podcasts
CALGB 49907 trial: Standard chemotherapy versus capecitabine for older women with early stage breast cancer | Dr Hyman Muss at ASCO 2015
At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Hyman Muss, MD, of the University of North Carolina, Chapel Hill, NC, provides an update on the CALGB/CTSU/Alliance 49907 trial...
Author: EMJ
Added: 08/20/2015 (Source: Oncology Tube)
Source: Oncology Tube - August 20, 2015 Category: Cancer & Oncology Source Type: podcasts
Resected Pancreatic Cancer: Why Wait for the Inevitable?
Dr. John Marshall reports on a retrospective study suggesting that maintenance with capecitabine is a promising option in patients with resected pancreatic adenocarcinoma after adjuvant therapy. (Source: Medscape Gastroenterology Podcast)
Source: Medscape Gastroenterology Podcast - April 4, 2014 Category: Gastroenterology Authors: Medscape Source Type: podcasts
